New hope for Hard-to-Treat breast cancer: Two-Drug combo shows promise
NCT ID NCT07520760
First seen Apr 10, 2026 · Last updated Jun 09, 2026 · Updated 10 times
Summary
This study tests a combination of two drugs, eribulin and anlotinib, in people with HER2-negative advanced breast cancer who have already tried other treatments like antibody-drug conjugates but their cancer continued to grow. The goal is to see if this new pair can slow down or stop the cancer from getting worse. About 52 participants will take part, and researchers will track how long they live without the cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER-2 NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.